ANS014004 / Avistone Biotech - LARVOL DELTA

ANS014004, a new generation of targeted drug, has finally started clinical trials and is now recruiting patients with solid tumors [Google translation] (vbdata.cn) - "ANS014004, a new generation targeted drug, has started clinical trials to recruit patients with solid tumors. The drug is a type II MET TKI with good anti-tumor activity. Domestic patients can join the group through consultation on the Global Oncology Doctors Network."

Trial status • Oncology • Solid Tumor

Avistone Announces Updates on ANS014004 (Businesswire) - "Beijing Avistone Biotechnology Co., Ltd...announced that the Phase I dose escalation study evaluating ANS014004 ('ANS01'), a novel small-molecule type II c-Met tyrosine kinase inhibitor (TKI) was recently cleared to proceed with enrollment of patients in Canada by Health Canada."

Trial status • Oncology • Solid Tumor

A Study to Investigate ANS014004 in Participants With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=63 | Recruiting | Sponsor: Avistone Biotechnology Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Metastases • Oncology • Solid Tumor

A Study to Evaluate ANS014004 in Subjects With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=216 | Recruiting | Sponsor: Avistone Biotechnology Co., Ltd.

Metastases • Monotherapy • New P1 trial • Oncology • Solid Tumor

A Study to Investigate ANS014004 in Participants With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=63 | Not yet recruiting | Sponsor: Avistone Biotechnology Co., Ltd.

Metastases • New P1 trial • Oncology • Solid Tumor

Avistone Announces Preclinical Results for ANS014004, a Type II c-Met Tyrosine Kinase Inhibitor (TKI) at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (Businesswire) - "Avistone Biotechnology...announced results from its China and US IND enabling nonclinical studies for ANS014004 ('ANS01'), a novel small-molecule type II c-Met tyrosine kinase inhibitor (TKI). The data were presented today (Poster# C145) at the AACR-NCI-EORTC meeting hosted by the American Association for Cancer Research (AACR), the National Cancer Institute (NCI), and the European Organisation for Research and Treatment of Cancer (EORTC).....Overall, the non-clinical studies of ANS014004 demonstrated it is a potent, orally-bioavailable type II c-Met inhibitor with activity against various pathogenetic MET alterations and with favorable absorption, distribution, pharmacokinetic, efficacy, and tolerability profiles in vivo. The molecule will enter Phase 1 clinical studies in both China and the US soon."

Preclinical • Oncology